QUALITY GUARANTEE

If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.

Quality test failed? Free replacement or full refund.

Off-spec? Free replacement or full refund.

FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →

FDA PCAC: 7 peptides under review. Read →

CJC-1295 without DAC

Name: CJC-1295 without DAC
Brand: Vialdyne
SKU: cjc-1295

Modified GRF 1-29 · GHRH analog

≥ 99.0%GH-Axis Peptides

Batch documentation

CJC-1295 no-DAC batch documentation and combination options

For CJC-1295 no-DAC or CJC-1295 + Ipamorelin sourcing, review the offered form, counter-ion, fill sizes, and batch records against your QA requirements.

Ask sales for the batch COA for the requested product or combination.
Confirm sequence-verification requirements and any additional testing in the agreed written scope.
Agree fill sizes and documentation requirements before placing a recurring order.

Overview

CJC-1295 without DAC, also catalogued as Modified GRF 1-29 or ModGRF 1-29, is a 29-residue GHRH analogue carrying four engineered substitutions (Ala2 to D-Ala, Asn8 to Gln, Gly15 to Ala, Met27 to Leu) that block DPP-4 cleavage and slow serum protease degradation. Receptor pharmacology is GHRH-receptor-mediated, and the resulting GH-release pattern is pulsatile and closely resembles native physiological secretion, in contrast to the DAC variant, whose covalent albumin conjugation pushes plasma half-life into the once-weekly range and flattens the pulse architecture. For compounding pharmacy buyers, Vialdyne releases CJC-1295 no-DAC as the lyophilised acetate against a ≥99.0% main-peak HPLC specification. The no-DAC form is most commonly paired with a GHSR-axis agonist (Ipamorelin, occasionally GHRP-2 or GHRP-6) in dual-pathway compounding protocols; the canonical CJC-1295 + Ipamorelin pairing is supplied directly as a pre-blended co-lyophilised vial under the cjc-1295-ipamorelin SKU, which removes the in-cleanroom blending step, with the measured ratio available on request on the released-batch COA. The companion CJC-1295 + Ipamorelin pharmacology article covers the dual-pathway rationale in detail. Catalogue strengths are 2, 5, and 10 mg; the 2 and 5 mg fills are the typical dispensing vials in 503A workflows.

Applications & buyer fit

GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.

How CJC-1295 without DAC is sourced

Sourced for

503A / 503B compounding dispensed under physician supervision
Research into somatotropic-axis pharmacology

Buyer fit

academic and contract research laboratories
503A / 503B compounding pharmacies

Documentation that ships

Certificate of Analysis (COA)
HPLC Chromatogram
Mass-spec identity (ESI-MS)
Counter-ion (acetate vs TFA)
Sterile-fill release pack (sterility, CCI, fill-weight)
Bacterial endotoxin (LAL, USP <85>)
Stability data on request
SDS / MSDS

Procurement note: For sterile-filled vials, confirm whether sterility, endotoxin, and CCI are included in the agreed release packet. For loose lyophilized powder, request the batch COA and separately scope any sequence-level evidence required by the buyer's written procedure.

Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.

Specifications

CAS: No single public CAS for the without-DAC (Mod-GRF 1-29) form; identity per batch COA
Appearance: White to off-white lyophilized powder
Purity (HPLC): ≥ 99.0%
Strength: 2 mg – 10 mg
Packaging: 10 vials/box · base pack (multiples of 10)
MOQ: On request
Lead time: 7–14 days
Storage: -20°C, protect from light

Certificate of Analysis

Representative COA previews for CJC-1295 without DAC; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

CJC-1295 without DAC

VD260428-CND10055 · 99.17%

VerifiedRequest full COA →

CJC-1295 without DAC

VD260428-CND053 · 99.14%

VerifiedRequest full COA →

CJC-1295 without DAC

VD260428-CND5054 · 98.96%

Browse all published COAs

Regulatory note

Sold as a pharmaceutical-grade active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.

Frequently asked questions

What's the difference between CJC-1295 with DAC and without DAC?▾

The backbone is the same Modified GRF 1-29 sequence in both, but the DAC version carries an additional maleimido-propionyl modification at Lys30. In serum, the maleimide forms a covalent bond with the free thiol of Cys34 on human serum albumin, producing a circulating peptide-albumin conjugate that extends half-life from roughly 30 minutes (no-DAC) to about 6-8 days (DAC). The pharmacology is therefore fundamentally different: no-DAC produces a pulsatile GH-release pattern that mirrors physiological secretion, while DAC produces sustained GH elevation that overrides the natural pulse architecture. Most 503A compounding workflows and pulse-pharmacology research use the no-DAC form; sustained-elevation contexts are where DAC fits.

Why is CJC-1295 almost always combined with Ipamorelin in practice?▾

Because two receptor pathways converge on the same somatotroph cells and produce additive output. CJC-1295 signals through the GHRH receptor; Ipamorelin signals through the GHSR (ghrelin receptor). Combining a GHRH-pathway agonist with a GHSR-pathway agonist produces a measurably larger GH pulse than either component alone at matched individual doses. The standard combined-product ratio is 1:1 by mass (2+2 mg or 5+5 mg per vial are the typical fills). Vialdyne ships this as a pre-blended co-lyophilised vial under the cjc-1295-ipamorelin SKU, which is operationally preferred over having the receiving pharmacy combine two reconstituted vials inside the cleanroom because co-lyophilisation fixes the ratio in the cake; the measured ratio, rather than just the nominal target, is available on request and listed on the released-batch COA when tested.

How is CJC-1295 typically reconstituted and stored after opening?▾

The lyophilised cake dissolves cleanly in bacteriostatic water for injection at standard reconstitution concentrations. Solution stability at -20 C as single-use aliquots is reasonable, but the dominant operational driver of measured-potency loss in this class is freeze-thaw cycling, not slow temperature drift, so the practical guidance is to sub-divide immediately after reconstitution into the smallest workable single-use volumes and cap the cumulative thaw count at three or fewer per aliquot. The lyophilised vial itself rolls under the standard 24-month re-test window at -20 C, and the released-batch COA carries the documented re-test date for pharmacies planning recurring procurement cycles.

Related peptides

Buyers who view CJC-1295 without DAC also ask about:

Ipamorelin

≥99.0%

Ghrelin / GHSR pathway GH-release peptide

CAS: 170851-70-4
Vial: 2 mg–10 mg

MOQ on requestGet quote →

CJC 5mg + IPA 5mg

≥99.0%

GH-axis blend (CJC-1295 no DAC + Ipamorelin)

CAS: —
Vial: 10 mg

MOQ on requestGet quote →

29-mer

Sermorelin

≥99.0%

GHRH 1-29 fragment

CAS: 86168-78-7
Vial: 2 mg–10 mg

MOQ on requestGet quote →

CJC-1295 with DAC

≥99.0%

Long-acting GHRH analog with Drug Affinity Complex

CAS: 446262-90-4
Vial: 2 mg–10 mg

MOQ on requestGet quote →

See full catalog

CJC-1295 without DAC

Modified GRF 1-29 · GHRH analog

≥ 99.0%GH-Axis Peptides

Batch documentation

CJC-1295 no-DAC batch documentation and combination options

For CJC-1295 no-DAC or CJC-1295 + Ipamorelin sourcing, review the offered form, counter-ion, fill sizes, and batch records against your QA requirements.

Ask sales for the batch COA for the requested product or combination.
Confirm sequence-verification requirements and any additional testing in the agreed written scope.
Agree fill sizes and documentation requirements before placing a recurring order.

Overview

Applications & buyer fit

How CJC-1295 without DAC is sourced

Sourced for

503A / 503B compounding dispensed under physician supervision
Research into somatotropic-axis pharmacology

Buyer fit

academic and contract research laboratories
503A / 503B compounding pharmacies

Documentation that ships

Certificate of Analysis (COA)
HPLC Chromatogram
Mass-spec identity (ESI-MS)
Counter-ion (acetate vs TFA)
Sterile-fill release pack (sterility, CCI, fill-weight)
Bacterial endotoxin (LAL, USP <85>)
Stability data on request
SDS / MSDS

Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.

Specifications

CAS: No single public CAS for the without-DAC (Mod-GRF 1-29) form; identity per batch COA
Appearance: White to off-white lyophilized powder
Purity (HPLC): ≥ 99.0%
Strength: 2 mg – 10 mg
Packaging: 10 vials/box · base pack (multiples of 10)
MOQ: On request
Lead time: 7–14 days
Storage: -20°C, protect from light

Certificate of Analysis

VerifiedRequest full COA →

CJC-1295 without DAC

VD260428-CND10055 · 99.17%

VerifiedRequest full COA →

CJC-1295 without DAC

VD260428-CND053 · 99.14%

VerifiedRequest full COA →

CJC-1295 without DAC

VD260428-CND5054 · 98.96%

Browse all published COAs

Regulatory note

Frequently asked questions

What's the difference between CJC-1295 with DAC and without DAC?▾

Why is CJC-1295 almost always combined with Ipamorelin in practice?▾

How is CJC-1295 typically reconstituted and stored after opening?▾

Related peptides

Buyers who view CJC-1295 without DAC also ask about:

Ipamorelin

≥99.0%

Ghrelin / GHSR pathway GH-release peptide

CAS: 170851-70-4
Vial: 2 mg–10 mg

MOQ on requestGet quote →

CJC 5mg + IPA 5mg

≥99.0%

GH-axis blend (CJC-1295 no DAC + Ipamorelin)

CAS: —
Vial: 10 mg

MOQ on requestGet quote →

29-mer

Sermorelin

≥99.0%

GHRH 1-29 fragment

CAS: 86168-78-7
Vial: 2 mg–10 mg

MOQ on requestGet quote →

CJC-1295 with DAC

≥99.0%

Long-acting GHRH analog with Drug Affinity Complex

CAS: 446262-90-4
Vial: 2 mg–10 mg

MOQ on requestGet quote →

See full catalog